Loading

Biosyngen Pte Ltd

June 16, 2025
Company Presentation
Cell and Gene Therapy and Genome Editing
Biosyngen, a biotechnology company headquartered in Singapore that focuses on unmet therapeutic needs in cancer patients. Biosyngen develops first-in-class immunotherapy-based strategies to provide cancer patients with innovative drugs, overcoming refractoriness to standard-of-care treatments. Over the last eight years, Biosyngen has made remarkable achievements in developing a unique portfolio to target multiple solid tumors with proprietary designed cytotoxic T-cells including next-gen CAR-T, TCR-T and TILs to halt the progression of life-threatening advanced solid tumors. Biosyngen has established locally largest GMP facility in Singapore and China to serve patients globally. Biosyngen intends to be a global leader worldwide, having already established strategic collaborations with the most prestigious cancer centers. Bioyngen has secured 8 FDA and NMPA approved INDs, with two fast-track designations, and 2 phase 2 clinical trial clearances targeting a wide range of solid tumors.
Biosyngen Pte Ltd
Company HQ City: Singapore
Company HQ Country: Singapore
Year Founded: 2016
Lead Product in Development: BRG01-CAR-T targeting nasopharyngeal cancer & EBV+ Lymphomas

CEO

Michelle Chen

Year Founded

2016

Development Phase of Lead Product

Phase II

Number of Unlicensed Products Looking for Licensing

5

What is your next catalyst (value inflection) update?

Jan 2025

Website

www.biosyngen.com
Primary Speaker
Hao Shen
Hao Shen, PhD
President
Biosyngen Pte Ltd

BIO DOUBLE HELIX SPONSORS

Our sponsors help support BIO's mission to support and advocate for the biotechnology industry.

Loading

BIO HELIX SPONSORS